DAB389-IL-6

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDAB389-IL-6
Drug Alias NameIL-6 fusion toxin (Ligand)IL-6 fusion toxin (Seragen)IL-6 fusion toxin (Seragen/Ligand)interleukin-6 fusion toxin (Seragen)interleukin-6 fusion toxin (Ligand) +[7] 
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionIL-6 receptor agonists
TargetsIL-6 receptor
Therapy Area/IndicationsMyeloproliferative DisordersSarcoma, Kaposi
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSeragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeragen IncLigand Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMyeloproliferative DisordersSarcoma, Kaposi

Other Information

ATC CodeN/A
Related LinksN/A